This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Clover Biopharmaceuticals 관리
관리 기준 확인 0/4
Clover Biopharmaceuticals' CEO is Joshua G. Liang, appointed in Dec 2020, has a tenure of 2.75 years. total yearly compensation is CN¥30.29M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 1.48% of the company’s shares, worth HK$18.53M. The average tenure of the management team and the board of directors is 1.7 years and 2 years respectively.
주요 정보
Joshua G. Liang
최고 경영자
CN¥30.3m
총 보상
CEO 급여 비율 | 26.9% |
CEO 임기 | 2.8yrs |
CEO 소유권 | 1.5% |
경영진 평균 재임 기간 | 1.7yrs |
이사회 평균 재임 기간 | 2yrs |
최근 관리 업데이트
Recent updates
CEO 보상 분석
날짜 | 총 보상 | 급여 | 회사 수익 |
---|---|---|---|
Jun 30 2023 | n/a | n/a | -CN¥665m |
Mar 31 2023 | n/a | n/a | -CN¥2b |
Dec 31 2022 | CN¥30m | CN¥8m | -CN¥2b |
Sep 30 2022 | n/a | n/a | -CN¥4b |
Jun 30 2022 | n/a | n/a | -CN¥6b |
Mar 31 2022 | n/a | n/a | -CN¥6b |
Dec 31 2021 | CN¥15m | CN¥8m | -CN¥6b |
Dec 31 2020 | CN¥4m | CN¥4m | -CN¥913m |
보상 대 시장: Joshua G.'s total compensation ($USD4.14M) is above average for companies of similar size in the Hong Kong market ($USD335.32K).
보상과 수익: Joshua G.'s compensation has increased whilst the company is unprofitable.
CEO
Joshua G. Liang (30 yo)
2.8yrs
테뉴어
CN¥30,285,000
보상
Mr. Joshua G. Liang is Executive Director and Chief Executive Officer at Clover Biopharmaceuticals, Ltd. since December 25, 2020. Mr. Liang is primarily responsible for leading the management and operation...
리더십 팀
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
Founder | 4.9yrs | CN¥10.45m | 16.19% CN¥ 203.2m | |
CEO & Executive Director | 2.8yrs | CN¥30.29m | 1.48% CN¥ 18.5m | |
Chief Financial Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
Chief Technology Officer | less than a year | 데이터 없음 | 데이터 없음 | |
Director of Investor Relations | less than a year | 데이터 없음 | 데이터 없음 | |
Executive Director of Corporate Communications | less than a year | 데이터 없음 | 데이터 없음 | |
Chief People Officer | 1.8yrs | 데이터 없음 | 데이터 없음 | |
Chief Medical Officer of Vaccine | 2.6yrs | 데이터 없음 | 데이터 없음 | |
Chief Technical Operation Officer | no data | 데이터 없음 | 데이터 없음 | |
Senior Vice President of Corporate Strategy & Business Development | 1.8yrs | 데이터 없음 | 데이터 없음 | |
Senior Vice President of Head of Regulatory Affairs | 1.8yrs | 데이터 없음 | 데이터 없음 | |
President of Global Research & Development | 1.6yrs | 데이터 없음 | 데이터 없음 |
1.7yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: 2197's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
이사회 구성원
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
Founder | 4.9yrs | CN¥10.45m | 16.19% CN¥ 203.2m | |
CEO & Executive Director | 2.8yrs | CN¥30.29m | 1.48% CN¥ 18.5m | |
Independent Non-Executive Director | 2yrs | CN¥2.21m | 0.011% CN¥ 143.2k | |
Non-Executive Director | 1.3yrs | CN¥1.30m | 0.039% CN¥ 484.8k | |
Non-Executive Director | 2.5yrs | CN¥2.20m | 2.18% CN¥ 27.3m | |
Non-Executive Director | 1.3yrs | CN¥527.00k | 0.0067% CN¥ 84.6k | |
Independent Non-Executive Director | 2yrs | CN¥2.32m | 0.011% CN¥ 143.2k | |
Independent Non-executive Director | 2yrs | CN¥2.29m | 0.011% CN¥ 143.2k | |
Independent Non-Executive Director | 2yrs | CN¥2.21m | 0.011% CN¥ 143.2k |
2.0yrs
평균 재임 기간
61yo
평균 연령
경험이 풍부한 이사회: 2197's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.